Cytokines and chemotherapy: A new approach to therapy for solid tumors

J. H. Freimann, Avi Markowitz

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Based on the promising results of preclinical studies, the synergistic activity between cytokines and chemotherapeutic agents has been investigated in clinical trials. Anti-tumor activity and alterations in the spectrum of toxicity of the single modalities have been reported. However, definitive evidence for clinically relevant synergy remains unproven. In addition, optimal doses and schedules of these combinations have not yet been determined. Uncovering the mechanism of action for a specific combination may allow future studies to exploit this preclinical synergy.

    Original languageEnglish (US)
    Pages (from-to)224-232
    Number of pages9
    JournalCancer Bulletin
    Volume43
    Issue number3
    StatePublished - 1991

    Fingerprint

    Appointments and Schedules
    Clinical Trials
    Cytokines
    Drug Therapy
    Neoplasms
    Therapeutics

    ASJC Scopus subject areas

    • Cancer Research

    Cite this

    Freimann, J. H., & Markowitz, A. (1991). Cytokines and chemotherapy: A new approach to therapy for solid tumors. Cancer Bulletin, 43(3), 224-232.

    Cytokines and chemotherapy : A new approach to therapy for solid tumors. / Freimann, J. H.; Markowitz, Avi.

    In: Cancer Bulletin, Vol. 43, No. 3, 1991, p. 224-232.

    Research output: Contribution to journalArticle

    Freimann, JH & Markowitz, A 1991, 'Cytokines and chemotherapy: A new approach to therapy for solid tumors', Cancer Bulletin, vol. 43, no. 3, pp. 224-232.
    Freimann, J. H. ; Markowitz, Avi. / Cytokines and chemotherapy : A new approach to therapy for solid tumors. In: Cancer Bulletin. 1991 ; Vol. 43, No. 3. pp. 224-232.
    @article{6696bd3648544cd1acb5d6544703183d,
    title = "Cytokines and chemotherapy: A new approach to therapy for solid tumors",
    abstract = "Based on the promising results of preclinical studies, the synergistic activity between cytokines and chemotherapeutic agents has been investigated in clinical trials. Anti-tumor activity and alterations in the spectrum of toxicity of the single modalities have been reported. However, definitive evidence for clinically relevant synergy remains unproven. In addition, optimal doses and schedules of these combinations have not yet been determined. Uncovering the mechanism of action for a specific combination may allow future studies to exploit this preclinical synergy.",
    author = "Freimann, {J. H.} and Avi Markowitz",
    year = "1991",
    language = "English (US)",
    volume = "43",
    pages = "224--232",
    journal = "Cancer Bulletin",
    issn = "0008-5448",
    publisher = "Medical Arts Publishing",
    number = "3",

    }

    TY - JOUR

    T1 - Cytokines and chemotherapy

    T2 - A new approach to therapy for solid tumors

    AU - Freimann, J. H.

    AU - Markowitz, Avi

    PY - 1991

    Y1 - 1991

    N2 - Based on the promising results of preclinical studies, the synergistic activity between cytokines and chemotherapeutic agents has been investigated in clinical trials. Anti-tumor activity and alterations in the spectrum of toxicity of the single modalities have been reported. However, definitive evidence for clinically relevant synergy remains unproven. In addition, optimal doses and schedules of these combinations have not yet been determined. Uncovering the mechanism of action for a specific combination may allow future studies to exploit this preclinical synergy.

    AB - Based on the promising results of preclinical studies, the synergistic activity between cytokines and chemotherapeutic agents has been investigated in clinical trials. Anti-tumor activity and alterations in the spectrum of toxicity of the single modalities have been reported. However, definitive evidence for clinically relevant synergy remains unproven. In addition, optimal doses and schedules of these combinations have not yet been determined. Uncovering the mechanism of action for a specific combination may allow future studies to exploit this preclinical synergy.

    UR - http://www.scopus.com/inward/record.url?scp=0025820713&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0025820713&partnerID=8YFLogxK

    M3 - Article

    AN - SCOPUS:0025820713

    VL - 43

    SP - 224

    EP - 232

    JO - Cancer Bulletin

    JF - Cancer Bulletin

    SN - 0008-5448

    IS - 3

    ER -